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ttp://dx.doi.org/10.1016/j.ajpath.2014.12.016Methionine adenosyltransferase 2B (MAT2B) encodes for variant proteins V1 and V2 that interact with
GIT1 to increase ERK activity and growth in human liver and colon cancer cells. MAT2B or GIT1 over-
expression activates MEK. This study explores the mechanism for MEK activation. We examined protein-
protein interactions by co-immunoprecipitation and veriﬁed by confocal microscopy and pull-down assay
using recombinant or in vitro translated proteins. Results were conﬁrmed in an orthotopic liver cancer
model. We found that MAT2B and GIT1-mediated MEK1/2 activation was not mediated by PAK1 or Src in
HepG2 or RKO cells. Instead, MAT2B and GIT1 interact with B-Raf and c-Raf and enhance recruitment of
Raf proteins to MEK1/2. MAT2B-GIT1 activates c-Raf, which is the key mediator for MEK/12 activation,
because this still occurred in RKO cells that express constitutively active B-Raf mutant. The mechanism
lies with the ability of MAT2B-GIT1 to activate Ras and promote B-Raf/c-Raf heterodimerization.
Interestingly, MAT2B but not GIT1 can directly interact with Ras, which increases protein stability.
Finally, increased Ras-Raf-MEK signaling occurred in phenotypically more aggressive liver cancers
overexpressing MAT2B variants and GIT1. In conclusion, interaction between MAT2B and GIT1 serves as a
scaffold and facilitates signaling in multiple steps of the Ras/Raf/MEK/ERK pathway, further emphasizing
the importance of MAT2B/GIT1 interaction in cancer growth. (Am J Pathol 2015, 185: 1135e1144;
http://dx.doi.org/10.1016/j.ajpath.2014.12.016)Supported by NIH grant R01DK51719 (S.C.L. and J.M.M.); Plan
Nacional of IþD SAF 2011-29851, Departamento de Educación del
Gobierno Vasco (J.M.M.); and grant P30DK48522 from the Imaging Core
of the USC Research Center for Liver Diseases.
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expressed in all mammalian cells that catalyzes the formation of
S-adenosylmethionine (SAMe), the principal biological methyl
donor.1 There are three mammalian MAT genes. MAT1A and
MAT2A encode for the catalytic subunit (a1 and a2) of the
different MAT isoforms, and MAT2B encodes for a regulatory
subunit (b) that modulates the activity of the MAT2A-encoded
isoenzyme (MATII).1 MAT1A is predominantly expressed in
normal hepatocytes, whereas MAT2A is expressed in all
extrahepatic tissues.1 MAT2B shares a similar expression
pattern as MAT2A.2 There are two major variant proteins
encoded by MAT2B, MAT2BV1 (or V1) and MAT2BV2
(or V2), and both variants can increase MATII efﬁciency by
lowering the Michaelis constant of MATII for its substratesstigative Pathology.
.methionine and ATP.2,3 In addition to regulating the kinetic
properties ofMATII,MAT2B is overexpressed in hepatocellular
carcinoma (HCC) and colon cancer and offers the cancer cell a
growth advantage.2,4
A key mechanism for MAT2B to enhance growth is
ERK1/2 activation.2,4 Our previous work found that
increased ERK1/2 activation occurs only when both MAT2B
Peng et alvariants are present in addition to GIT1, a scaffold protein
that facilitates c-Srcedependent mitogen-activated protein
kinase (MAPK) activation.4 We found that both MAT2B
variants directly interact with GIT1, and when these proteins
are overexpressed, there is enhanced recruitment of ERK2 to
MEK1 and the activity of both ERK1/2 and MEK1
increased.4 This ﬁnding proved to be important in tumori-
genesis because overexpression of either V1 or V2with GIT1
enhanced growth and lung metastasis in an orthotopic HCC
model.4 Conversely, knockdown of endogenous V1, V2, or
GIT1 lowered MEK1 and ERK1/2 activity.4 Thus, our pre-
vious work established MAT2B-GIT1 as a scaffold that
facilitates MEK-ERK signaling.4 However, we did not
examine how MAT2B-GIT1 complex activates MEK. Our
current work examined the signaling pathways that can lead
to MEK activation and identiﬁed MAT2B-GIT1 as a scaffold
that acts on multiple levels of the Ras-Raf-MEK-ERK
signaling cascade to facilitate their activation in human
liver and colon cancer cells.
Materials and Methods
Cell Culture
HepG2, Hep3B, SW480, and RKO cell lines were obtained
from the Cell Separation and Culture Core facility at the
University of Southern California Research Center for Liver
Diseases. NCM460 normal colon epithelial cells were from
INCELL Corporation (San Antonio, TX) and grown in
M3:base cell culture medium supplemented with 10% fetal
bovine serum at 37C in a 5% CO2 humidiﬁed incubator.
HepG2 cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (Corning, Manassas, VA) and Hep3B and
RKO cells in modiﬁed Eagle’s medium (Corning) each with
10% fetal bovine serum (Seradigm, Radnor, PA). SW480
cells were maintained in L15 medium (Corning) with 10%
fetal bovine serum in a humidiﬁed incubator without CO2.
Transfection and Quantitative PCR
Human GIT1 and MAT2B V1 and V2 expression plasmids
were described previously.4 siRNA against GIT1 was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA),
and siRNA against V1 and V2 were described previously.4
For gene overexpression experiments, 1.5  105 HepG2,
Hep3B, RKO, and SW480 cells in 12-well plates were
transiently transfected with V1, V2, GIT1 expression plas-
mids, or empty vector using Superfect (Qiagen, Valencia,
CA) according to the manufacturer’s protocol. For gene
knockdown studies, 10 nmol/L siRNA against V1 and V2, 8
nmol/L siRNA against GIT1 (Santa Cruz Biotechnology), or
10 nmol/L scramble control were delivered into HepG2 or
RKO cells by Lipofectamine RNAiMAX (Life Technolo-
gies, Grand Island, NY) following the manufacturer’s pro-
tocol. For combination overexpression and knockdown
experiments, 1.5  105 RKO cells were co-transfected with113610 nmol/L siRNA against c-Raf (Santa Cruz Biotechnology)
and 1 mg of V1, V2, or GIT1 expression vector. Equal
amounts of scramble control siRNA plus empty vector were
used as a control. Forty-eight hours after transfection, total
RNA or whole cell lysates were prepared for real-time
quantitative PCR and Western blotting, respectively. Total
RNA isolation, cDNA synthesis, real-time quantitative,
primers, and Taqman probes were described previously.4
Probes for c-Raf, H-Ras, and K-Ras were purchased from
Life Technologies.
Western Blotting
For Western blotting, 20 mg of whole cell extract were sepa-
rated by 10% SDS-PAGE. Blots were probed with antibodies
against phospho (p)-MEK1/2 (S218/222), p-MEK1/2 (S298),
total MEK/12, p-c-Raf (S338), total c-Raf, p-B-Raf (T598/
S601), total B-Raf, pSrc (Y416), total Src, pan Ras, K-Ras
(Santa Cruz Biotechnology), GIT1, MAT2B, b-actin (Sigma,
St Louis, MO), or V5 (Life Technologies). Western blotting
was performed as previously described.2,4
Immunoprecipitation Studies
Immunoprecipitation studies were performed as described
previously.4 Brieﬂy, cells were lyzed in a modiﬁed radio-
immunoprecipitation assay buffer with protease and phos-
phatase inhibitors. A total of 500 mg of whole cell lysate was
used to co-immunoprecipitate with antibodies against
MAT2B, GIT1, MEK1/2, or B-Raf. Western blots were
performed to detect MAT2B, GIT1, V5, MEK1/2, c-Raf,
B-Raf, PAK1, Ras, and SOS1/2. Clean Blot IP Detector
Reagent (Thermo Scientiﬁc, Rockford, IL) was used to
reduce background. Normal IgG (Santa Cruz Biotech-
nology) was used as a control.
In Vitro Translation and Protein Binding Assay
Full-length human MEK1 from pEGFP-N1-MEK1 (Addg-
ene plasmid 14746; Addgene, Cambridge, MA) was
subcloned into p-CDNA3.1-V5-His vector (Life Technolo-
gies) to generate p-CDNA3.1-V5-His-MEK1. Human
B-Raf expression plasmid p-cDNA3.1-Hygro-BRaf was
obtained from Addgene (Addgene plasmid 40775). Human
GIT1 expression plasmid Xpress-GIT1was a gift from Dr.
Bradford C. Berk (University of Rochester, Rochester, NY).
In vitro transcription translation of full-length GIT1 or B-Raf
proteins was performed using the TNT Quick Coupled
Transcription/Translation System (Promega, Madison, WI) as
per the manufacturer’s protocol.
Human c-Raf recombinant protein (rc-Raf) was pur-
chased from GeneTex (Irvine, CA). Human Ras recombi-
nant protein (rRas) was purchased from Cytoskeleton, Inc.
(Denver, CO). Recombinant human MAT2B protein
(rMAT2B) was from Novus. In vitro pull-down assay was
performed as described previously.4 To determine theajp.amjpathol.org - The American Journal of Pathology
Figure 1 Methionine adenosyltransferase 2B (MAT2B) and GIT1
interact with c-Raf and B-Raf and enhance their recruitment to MEK when
overexpressed. A: Immunoprecipitation (IP) of cell lysates (Lys) from RKO
and HepG2 cells for MEK, MAT2B, and GIT1 were immunoblotted with an-
tibodies to MAT2B, MEK1/2, GIT1, c-Raf, and B-Raf. Normal IgG was used as
a negative control, whereas 1% of cell lysates used in IP were loaded as
input. B: RKO or HepG2 cells were transfected with overexpression vectors
for V1, V2, GIT1, or empty vector (Vec) as described in Materials and
Methods followed by IP for MEK1/2 and immunoblotting for B-Raf, c-Raf,
PAK1, and MEK1/2. Numbers below the blots represent mean densitometric
values normalized to MEK1/2 from at least three independent experiments
expressed as fold over vector control. C: In vitro pull-down assay using
immobilized MEK1 plus B-Raf, with MAT2B or GIT1 alone or together. Note
that MAT2B and GIT1 must both be present to enhance recruitment of B-Raf
to MEK1. D: In vitro pull-down assay with immobilized MEK1 plus c-Raf,
with MAT2B or GIT1 alone or together. Both MAT2B and GIT1 must be
present to enhance recruitment of c-Raf to MEK1. E and F: Immunoﬂuo-
rescence detection of MAT2B (green), B-Raf or c-Raf (red), and nuclei
(blue) in HepG2 cells. Merged images are shown in the bottom right of each
panel, in which yellow color shows cytoplasmic co-localization of MAT2B
and B-Raf (E) or c-Raf (F). Data are representative of at least three inde-
pendent experiments (AeD). *P < 0.05 versus Vec.
Ras/Raf/MEK Activity Regulationinﬂuence of MAT2B and GIT1 on recruitment of B-Raf or
c-Raf to MEK1, MEK1 protein was immobilized to protein
A/G plus agarose (Santa Cruz Biotechnology) by incubating
the protein with anti-MEK1 antibody for 16 hours and then
incubating the two with the beads for an additional 2 hours
at 4C. The complex was then washed and incubated withThe American Journal of Pathology - ajp.amjpathol.orgfull-length human B-Raf protein or rc-Raf protein for 2
hours, then rMAT2B, in vitro transcription-translation GIT1
(IVTGIT1), or both were added for an additional 16 hours,
after which the beads were washed six times with protein-
binding buffer. The protein-binding complexes were
resolved on SDS-PAGE gel and detected by Western blot.
To determine whether MAT2B and GIT1 enhance recruit-
ment of B-Raf to c-Raf, human rc-Raf protein immobilized
to protein A/G plus agarose was incubated with IVTB-Raf
for 2 hours, then IVTGIT1 and rMAT2B proteins were added
and incubated for 16 hours, after which the beads were
washed. To determine direct interactions between Ras and
MAT2B or GIT1, human rRas protein immobilized to
protein A/G plus agarose was incubated with rMAT2B or
IVTGIT1 alone or together for 16 hours and beads were
washed. To determine whether MAT2B and GIT1 enhance
recruitment of c-Raf and B-Raf to Ras, immobilized rRas
protein was incubated with IVTB-Raf plus rc-Raf proteins
for 4 hours, then rMAT2B plus IVTGIT1 proteins were
added for 16 hours, after which beads were washed.
Immunoﬂuorescence and Confocal Microscopy
Immunolabeling of MAT2B and B-Raf or c-Raf proteins in
the same cell was performed according to a standard pro-
tocol (Jackson ImmunoResearch Laboratories, West Grove,
PA), with minor modiﬁcations. Antibodies used are from
Jackson ImmunoResearch Laboratories unless indicated
otherwise. Brieﬂy, cells on the coverslips were incubated in
0.1% Triton X-100 in phosphate-buffered saline for 15
minutes at room temperature and then blocked in 5%
donkey serum for 1 hour. The coverslips were then incu-
bated with anti-MAT2B antibody (Sigma) at 1:100 dilution
for 2 hours, followed by incubation with a ﬂuorescein
isothiocyanateeconjugated donkey anti-rabbit antibody for
1 hour at room temperature. After washing, cells were
blocked in 5% goat serum, followed by incubation with
antieB-Raf or c-Raf antibodies (1:50 dilution; Santa Cruz
Biotechnology) for 2 hours and then with Cy3-conjugated
goat anti-mouse antibody for 1 hour, washed in phosphate-
buffered saline for 30 minutes, and mounted with mounting
medium that contained DAPI (Sigma). The images were
visualized and captured by an Eclipse TE300 confocal mi-
croscope (Nikon Instruments Inc., Melville, NY).
Ras Activity Assay
To evaluate Ras activation status, a Ras pull-down activation
assay (Cytoskeleton, Inc., Denver, CO) was performed
according to the manufacturer’s protocol. Brieﬂy, cell lysates
were incubated with glutathione S-transferaseetagged Raf1-
RBD protein bound to colored glutathione agarose beads for
1 hour at 4C with rotation. Beads that contained activated
Ras were collected by centrifugation, washed with wash
buffer provided by a kit, and prepared and separated by
SDS-PAGE. Activated Ras (c-Raf-RBD bound) was1137
Figure 2 The effect of methionine adenosyltransferase 2B (MAT2B) and
GIT1 on MEK is PAK1 and Src independent. A: RKO cells were treated with
siRNA against V1 (siV1), V2 (siV2), GIT1 (siGIT1), or scramble control (SC).
Protein levels of phospho (p)-MEK1/2 at S298 (site of phosphorylation by
PAK1), total MEK1/2, GIT1, and MAT2B were measured by Western blotting
after normalizing to b-actin housekeeping control. Graph summarizes the
densitometric values expressed as fold over SC from three independent
experiments. B: RKO cells were transfected with overexpression vectors of
V1, V2, GIT1, or empty vector (Vec) for 24 hours before 100 nmol/L
dasanitib (Dans) was added for an additional 24 hours. Protein levels of
p-MEK1/2 (S218/222), total MEK1/2, pSrc (Y416), and total Src were
measured by Western blotting after normalizing to b-actin housekeeping
control. Graph summarizes the densitometric values expressed as fold over
Vec. Results are means  SEM from three to four independent experiments
(B). *P < 0.05, **P < 0.01 versus respective controls. DMSO, dimethyl
sulfoxide.
Peng et alanalyzed by immunoblotting with a mouse monoclonal anti-
Pan Ras antibody provided by the kit. Activated Ras levels
were normalized to c-Raf-RBD level, and total Ras levels and
total Ras expression levels were normalized to actin levels.
Total cell lysates (500 mg) were loaded with GTPgS as a
positive control and GDP as a negative control for the
pull-down assay.
Orthotopic Liver Cancer Model
The orthotopic liver cancer model that allowed examination of
the effect of MAT2B V1 and V2 plus GIT1 overexpression
was previously described.4 Brieﬂy, 6-week-old male BALB/c
nude mice were injected in the left hepatic lobe with Huh-7
cells stably expressing MAT2BV1 and V2 or empty vector
(1  106 cells/50 mL) and concurrently under the same
anesthesia injected intrasplenically with lentiviral vector
expressing GIT1 or empty vector (2 109 transducing units in
0.05 mL). Two weeks later mice received tail vein injection
with the same lentiviral vector expressing GIT1 or empty
vector. All mice were sacriﬁced on day 21, when we reported
increased tumor volume and presence of lung metastasis in
those overexpressing V1 or V2 with GIT1.4 Tumors over-
expressing V1þGIT1, V2þGIT1, or VecþVec were pro-
cessed for co-immunoprecipitation and Western blotting as
above. All protocols, use, and the care of the animals were
reviewed and approved by the Institutional Animal Care and
Use Committee at the University of Southern California (Los
Angeles, CA).
Statistical Analysis
Densitometric values were measured using Quantity One
Software version 4.6.5 (BioRad Laboratories, Hercules,
CA). Data are given as means  SEM. Statistical analysis
was performed using analysis of variance followed by
Fisher’s test for multiple comparisons. All P values were
derived from at least three independent experiments. Sta-
tistical signiﬁcance was deﬁned by P < 0.05.
Results
MAT2B and GIT1 Interact with c-Raf and B-Raf to
Enhance Recruitment to MEK1/2 in Liver and Colon
Cancer Cells
Raf kinases, particularly c-Raf (same as Raf-1) and B-Raf,
are well known to activate MEK.5 We ﬁrst examined
whether GIT1 and MAT2B interact with c-Raf and B-Raf.
In both RKO and HepG2 cells, co-immunoprecipitation
experiments indicate that MAT2B and GIT1 interact with
c-Raf and B-Raf (Figure 1A). Furthermore, overexpression
of V1, V2, or GIT1 in both cell types led to increased
recruitment of both B-Raf and c-Raf to MEK1/2
(Figure 1B). Using an in vitro system, enhanced recruitment
of B-Raf and c-Raf to MEK1 occurred only when both1138MAT2B and GIT1 were present (Figure 1, C and D).
Finally, immunoﬂuorescence and confocal microscopy
conﬁrmed that endogenous MAT2B interact with B-Raf and
c-Raf in HepG2 cells (Figure 1, E and F).
We also examined whether the same interactions occur in
NCM460 cells, which are normal human colon epithelial
cells. Interestingly, although both MAT2B and GIT1
interact with each other as well as MEK1/2, c-Raf, and
B-Raf (Supplemental Figure S1A), overexpressing V1, V2,
or GIT1 failed to activate B-Raf, c-Raf, or MEK1/2
(Supplemental Figure S1B) or enhance recruitment of B-Raf
and c-Raf to MEK1/2 (Supplemental Figure S1C). In terms
of relative expression of MAT2B and GIT1, NCM460 cells
have 40% lower GIT1 mRNA levels compared with two
malignant colon cancer cells (RKO and SW480, which have
comparable expression). MAT2BV1 mRNA levels are
highest in RKO cells, followed by SW480, and lowest in
NCM460 cells at ratios of 3.8:2.6:1. However, MAT2BV2
mRNA levels are similar between NCM460 cells and RKOajp.amjpathol.org - The American Journal of Pathology
Figure 3 Methionine adenosyltransferase 2B
(MAT2B) and GIT1 expression regulate c-Raf and
B-Raf activity. A and B: HepG2 cells (expressing
wild-type c-Raf and B-Raf) were transfected with
V1, V2, GIT1 overexpression vector, or empty
vector (Vec) and processed for Western blotting for
phospho (p)-c-Raf (S338, active c-Raf) and total
c-Raf (A) and p-B-Raf (T598/S601, active B-Raf)
and total B-Raf (B). Numbers below the blots are
densitometric values expressed as fold over Vec
after normalizing to b-actin housekeeping control.
Ratios of p-c-Raf to total c-Raf and p-B-Raf to total
B-Raf are also shown. C: RKO cells (expressing
constitutively active B-Raf mutant but wild-type
c-Raf) were transfected with V1, V2, GIT1, or Vec
as above and processed for Western blotting for
active and total B-Raf and c-Raf. Numbers below
the blots are densitometric values expressed as
fold over Vec. Ratios of p-c-Raf to total c-Raf and
p-B-Raf to total B-Raf are also shown. D: RKO cells
were transfected with V1, V2, or GIT1 over-
expression vectors concurrent with knockdown of
c-Raf by siRNA versus scramble control (SC).
Protein levels of p-MEK1/2 (S218/222), total
MEK1/2, GIT1, V5 tag, and c-Raf were measured by
Western blotting and normalized to b-actin.
Numbers below the blots are densitometric values
expressed as fold over Vec. Ratios of p-MEK to total
MEK are also shown. E and F: HepG2 and RKO cells
were treated with SC, V1, V2, or GIT1 siRNA and
processed for Western blotting for p-c-Raf (S338,
active c-Raf) and total c-Raf. Numbers below the
blots are densitometric values expressed as fold
over SC after normalizing to b-actin housekeeping
control. Ratios of p-c-Raf to total c-Raf are also
shown. Results are representative of three inde-
pendent experiments (C and D). *P < 0.05 versus
Vec (AeD) or versus SC (E and F).
Ras/Raf/MEK Activity Regulationcells and both are approximately twofold higher than in
SW480 cells.
Effect of MAT2B-GIT1 on MEK1/2 Activation Is PAK1
and Src Independent
Besides Raf kinases, MEK1/2 activation can occur by
PAK1-mediated phosphorylation of MEK1 on S298, which
primes activation by c-Raf.6 However, overexpression of
V1, V2, or GIT1 did not increase interaction between
MEK1/2 and PAK1 (Figure 1B). Whereas knockdown of
V1, V2, or GIT1 lowered c-Rafemediated phosphorylation
of MEK1 on S218/S222 that is required for MEK1/2
activity,4,7 they had no effect on PAK1-mediated phos-
phorylation of MEK1/2 at S298 (Figure 2A). Another
potential mediator for increased MEK1/2 activation is Src
because it is able to stimulate c-Raf via phosphorylation of
tyrosine 341.8,9 We next investigated whether Src family
members may be involved using dasatinib, a potent inhibitorThe American Journal of Pathology - ajp.amjpathol.orgof Src kinase activity.10 Overexpression of V1, V2, or GIT1
increased p-MEK1 on S218/S222 and p-Src on Y416
(required for Src activity).11 Treatment with dasanitib
completely blocked Src activation as indicated by level of
p-Src Y416 but had no inﬂuence on MEK1/2 activation
(Figure 2B).
MAT2B and GIT1 Up-Regulate c-Raf and B-Raf Activity
and Their Heterodimerization
We next investigated whether MAT2B and GIT1 inﬂuenced
the activity of c-Raf and B-Raf. In HepG2 cells, which
express wild-type c-Raf and B-Raf,12 overexpression of V1,
V2, or GIT1 activated both Rafs as indicated by p-c-Raf on
S338 and p-B-Raf on T598 and S601 (Figure 3, A and B).8
In RKO cells, which express constitutively active B-Raf
mutant,13 overexpression of V1, V2, or GIT1 activated
c-Raf but had no inﬂuence on B-Raf activity (Figure 3C). In
both cell types, overexpression of V1, V2, or GIT1 also1139
Figure 4 Overexpression of methionine adenosyltransferase 2B
(MAT2B) and GIT1 enhances heterodimerization of B-Raf and c-Raf. A:
HepG2 cells (expressing wild-type c-Raf and B-Raf) overexpressing V1,
V2, GIT1, or empty vector (Vec) were subjected to immunoprecipitation
(IP) for B-Raf and immunoblotted for c-Raf and B-Raf as described in
Materials and Methods. One percentage of cell lysates (Lys) used in IP
were loaded as input. Graph summarizes the densitometric values
expressed as fold over Vec of c-Raf recruited to B-Raf. B: In vitro pull-
down assay with immobilized c-Raf plus in vitro transcription-
translation B-raf (IVTB-Raf), with or without MAT2B and GIT1. Graph
summarizes the densitometric values expressed as fold over c-RafþB-
Raf alone. Data are expressed as means  SEM from three independent
experiments (A and B). *P < 0.05 versus Vec (A) or versus c-RafþB-
Raf (B).
Figure 5 Methionine adenosyltransferase 2B (MAT2B) interacts with Ras
and enhances Ras expression and recruitment to B-Raf. A: HepG2 (expressing
mutant K-Ras and oncogenic dominant-acting N-Ras) and RKO (expressing
wild-type K-Ras) cells were transfected with V1, V2, GIT1 overexpression
vectors, or empty vector (Vec), and protein levels of pan Ras, K-Ras, V5 tag,
and GIT1 were measured by Western blotting after normalizing to b-actin.
Graphs summarize the densitometric values expressed as fold over Vec. B:
In vitro pull-down assay with immobilized Ras plus MAT2B and/or in vitro
transcription-translation GIT1 (IVTGIT1) shows that Ras directly interacts with
MAT2B but not GIT1. C: RKO cells overexpressing V1, V2, and GIT1 were
subjected to immunoprecipitation (IP) for B-Raf and immunoblotted for c-Raf,
pan Ras, and B-Raf. Normal IgG was used as a negative control, whereas 1% of
cell lysates (Lys) used in IP were loaded as input. Data are expressed
means  SEM from three independent experiments (A), blots from three
independent experiments (B), and fold over Vec from three independent
experiments (C). *P < 0.05 versus Vec.
Peng et alraised total c-Raf (but not B-Raf) protein levels (Figure 3,
AeC). This effect was not mediated at the mRNA level
because c-Raf mRNA levels were unchanged (Supplemental
Figure S2). To determine whether c-Raf is responsible for
V1-, V2-, and GIT1-mediated MEK1/2 activation, RKO
cells were treated with scramble or siRNA targeting c-Raf in
conjunction to overexpressing V1, V2, or GIT1. Over-
expression of V1, V2, or GIT1 activated MEK1/2 in the
scramble siRNA treated cells but not in those treated with c-
Raf siRNA (Figure 3D). In contrast, knockdown of V1, V2,
or GIT1 in both HepG2 (Figure 3E) and RKO (Figure 3F)
cells markedly reduced levels of active c-Raf, with less ef-
fect on total c-Raf.
Tomake sure the effects of overexpressing V1, V2, or GIT1
on activating B-Raf/c-Raf/MEK or recruiting B-Raf/c-Raf to
MEK1/2 were not unique to HepG2 and RKO cells, we also
examined this in SW480 and Hep3B cells, which are human
colon adenocarcinoma and hepatoma cell lines, respectively.
In both SW480 and Hep3B cells, overexpressing V1, V2, or
GIT1 activated B-Raf, c-Raf, and MEK1/2 and enhanced
recruitment of B-Raf and c-Raf to MEK1/2 (Supplemental
Figure S3).
Heterodimerization of c-Raf and B-Raf is known to
greatly enhance kinase activity compared with the1140respective homodimers or monomers.14 Overexpression of
V1, V2, or GIT1 in HepG2 cells enhanced interaction be-
tween B-Raf and c-Raf (Figure 4A), and in the in vitro
system, presence of MAT2B and GIT1 enhanced binding of
B-Raf to immobilized c-Raf (Figure 4B).MAT2B and GIT1 Activate Ras and Enhance
Recruitment of c-Raf to Ras
Ras proteins lie upstream of c-Raf and B-Raf in the signal-
transduction cascade. HepG2 cells express mutant K-Ras
and oncogenic dominant-acting N-Ras,12,15 whereas RKO
cells express mainly wild-type K-Ras.16 Interestingly,
overexpression of V1 or V2, but not GIT1, raised total Ras
protein levels in HepG2 cells and K-Ras in RKO cells
(Figure 5A). This effect lies at the protein level because theajp.amjpathol.org - The American Journal of Pathology
Figure 6 Methionine adenosyltransferase 2B (MAT2B) and GIT1 pro-
mote recruitment of c-Raf to Ras and activate Ras. A: In vitro pull-down
assay with immobilized Ras and in vitro transcription-translation B-Raf
(IVTB-Raf) and c-Raf, with or without MAT2B and IVTGIT1, reveals that the
presence of MAT2B and GIT1 enhances recruitment of c-Raf and perhaps
also B-Raf to Ras. B: Ras activity assay was measured as described in
Materials and Methods in RKO cells (expressing wild-type K-Ras) over-
expressing V1, V2, GIT1, or empty vector (Vec) for 48 hours. Results are
representative of three independent experiments. *P < 0.05 versus Vec.
Figure 7 Increased methionine adenosyltransferase 2B (MAT2B) and
GIT1 expression in hepatocellular carcinoma (HCC) enhances recruitment of
Ras/Raf/MEK Activity RegulationmRNA levels of H-Ras and K-Ras were unaffected
(Supplemental Figure S4). Using puriﬁed proteins in an
in vitro assay, direct interaction occurred between Ras and
MAT2B but not between Ras and GIT1 (Figure 5B). In
RKO cells, overexpression of V1, V2, or GIT1 enhanced
recruitment of not only c-Raf to B-Raf but also Ras to the
complex (Figure 5C). The presence of MAT2B and GIT1
also markedly enhanced recruitment of c-Raf and to a
smaller extent B-Raf to immobilized Ras (Figure 6A).
Finally, overexpression of V1, V2, or GIT1 in RKO cells
resulted in higher Ras activity even after normalizing for the
effect they have on total Ras expression (Figure 6B).c-Raf and B-Raf to MEK1, c-Raf activation, and interaction of B-Raf with
c-Raf and Ras. Liver tumors were derived from an orthotopic HCC model,
where Huh7 cells overexpressing MAT2BV1, V2, or empty vector (Vec) were
injected into the livers of nude mice and then subjected to a total of two
tail vein injections of a lentiviral vector overexpressing GIT1 or Vec during a
3-week period were used. A: Recruitment of c-Raf and B-Raf to MEK1 using
immunoprecipitation for MEK1 followed by immunoblotting for c-Raf and
B-Raf. B: Representative Western blots showing the expression level of
phospho (p)-c-Raf (S338), total c-Raf, MAT2B, and GIT1 in the tumors of
each treatment group. C: Recruitment of c-Raf and Ras to B-Raf using
immunoprecipitation (IP) for B-Raf followed by immunoblotting for c-Raf
and Ras. Graph summarizes the densitometric values normalized to MEK1
(A), b-actin (B), and B-Raf (C) expressed as fold over VecþVec from three
tumors per condition. *P < 0.05 versus VecþVec.HCC that Overexpresses V1/V2 Plus GIT1 Exhibits
Increased Interaction and Activation of Ras-Raf-MEK
Signaling
We previously found that use of an in vivo orthotopic HCC
model that increased V1, V2, or GIT1 expression individ-
ually enhanced tumor growth, but when V1 or V2 was
combined with GIT1, tumor growth was further enhanced
and distant metastasis occurred.4 Increased expression of V1
or V2 with GIT1 resulted in increased c-Raf and B-RafThe American Journal of Pathology - ajp.amjpathol.orgrecruitment to MEK1 (Figure 7A), higher activation of
c-Raf (Figure 7B), and enhanced interaction between B-Raf
and c-Raf and with Ras (Figure 7C).
Discussion
Until recently, MAT2B was only known in the regulation of
MATII enzymatic activity.1 Both MAT2B variants lower
the Michaelis constant of MATII for its substrates and V1
(same as the b subunit) also lowers the inhibitory constant
for SAMe.1,3 The ﬁrst indication that MAT2B is involved in
growth regulation of liver cancer cells was reported in 2003
by Martínez-Chantar et al,17 who found increased MAT2B
expression in human HCC and cirrhotic livers and corre-
lated increased liver cancer cell growth to lowering of the
SAMe level, consistent with its known effect on MATII1141
Peng et alactivity. Because a high SAMe level is growth inhibitory
and proapoptotic in liver cancer cells,1 the ability of
MAT2B to modulate liver cancer cell growth was thought to
be related to a change in the SAMe level.17 In 2008, we ﬁrst
reported the existence of multiple MAT2B splicing variants,
with V1 and V2 being dominant.2 The two variants differ
only by 20 amino acids at the 50 end but exhibit differential
tissue expression pattern and regulation by tumor necrosis
factor-a (positively regulates V1 at the promoter level but
not V2).2 In addition, although both variants are overex-
pressed in HCC and positively regulate growth, only V1 is
involved in apoptosis regulation.2 These ﬁndings suggest
that although they share many common features, they also
have distinct functions that may be independent of SAMe
regulation. Indeed, we later reported that both variants are
predominantly localized in the nuclear compartment and
interact with multiple proteins, including HuR, an mRNA-
binding protein known to stabilize the mRNA levels of
many genes, including cyclins, and GIT1.4,18 Over-
expression of V1 or V2 resulted in increased cytoplasmic
HuR content and higher mRNA levels of several cyclins,
which is one of the key mechanisms of MAT2B’s growth
inductive effect.18
Another key mechanism we identiﬁed is the ability of
MAT2B variants to form a scaffold complex with GIT1 in the
activation of MEK and ERK in both liver and colon cancer
cell lines.4 Overexpression of V1, V2, or GIT1 increased
MEK and ERK activity, whereas the opposite occurred when
their endogenous expression was reduced by siRNA.4
Interestingly, V1, V2, and GIT1 are all indispensable
because ERK activation and growth induction could not
occur if any of these were knocked down by siRNA.4 The
relevance of MAT2B-GIT1 interaction was conﬁrmed in
human HCC and colon cancer specimens, where their
expression was increased in most and their interaction
documented by co-immunoprecipitation.4 Enhanced
expression of V1 or V2 in conjunction with GIT1 was
particularly growth inductive in an orthotopic HCC model
and resulted in distant metastasis.4 Taken together, we
identiﬁed MAT2B-GIT1 as a key component required for
MEK-ERK signaling, but the mechanism(s) responsible for
MEK activation was unknown. The goal of our current work
was to elucidate how MAT2B-GIT1 activates MEK, and
during this work, we found that MAT2B-GIT1 is a scaffold
complex that regulates multiple steps in the Ras-Raf-MEK-
ERK signaling cascade.
MEK is an integral part of the Ras-Raf-MEK-ERK
MAPK signaling pathway, where activation of Ras fol-
lowed by Raf kinases phosphorylate two serine residues
(S218 and S222) in the activation loop of MEK, which in
turn activates ERK1/2.19 The MAPK cascade is not a linear
pathway because each member consists of a number of
components. In humans, three Ras genes encode four
distinct but highly homologous Ras proteins: H-Ras, N-Ras,
K-RasA, and K-RasB (the latter two are alternative splice
variants of the KRAS gene).20,21 Ras proteins are activated1142when GTP bound and inactivated when GDP bound.20
There are three Raf kinases (A-Raf, B-Raf, and c-Raf) that
share MEK1/2 as substrates, although A-Raf has very low
kinase activity toward MEK.5 HepG2 cells express onco-
genic dominant-acting N-Ras, and RKO cells express pre-
dominantly wild-type K-Ras.15,16 Although both cell types
express B-Raf and c-Raf, HepG2 cells express wild-type
Rafs and RKO cells express mutant B-Raf that is constitu-
tively active.13 In addition to Ras-mediated signaling, PAK1
and Src can also help activate MEK1/2. PAK1 phosphory-
lates MEK1 on S298, which primes activation by c-Raf.6
Src activates c-Raf by phosphorylating c-Raf on Y341.8,9
Given these considerations, we began our studies focusing
on the key players, namely, c-Raf, B-Raf, PAK1, and Src,
which can lead to MEK activation in HepG2 and RKO cells.
We found that MAT2B and GIT1 interact with both c-Raf
and B-Raf endogenously in HepG2 and RKO cells. More-
over, overexpression of V1, V2, or GIT1 enhanced
recruitment of these Raf kinases to MEK1/2. Importantly,
with the use of in vitro assays in which MEK1 was
immobilized, MAT2B and GIT1 enhanced recruitment of
B-Raf and c-Raf to MEK1 only if they were both present.
This result is consistent with our previous observation that
the effect on MEK/ERK activation and growth requires the
presence of both MAT2B and GIT1.4 We excluded PAK1
being involved in activating MEK for several reasons.
Overexpression of V1, V2, or GIT1 did not enhance inter-
action between MEK1/2 and PAK1. Knockdown of V1, V2,
or GIT1 lowered MEK activity4 but did not affect PAK1-
mediated phosphorylation of MEK1/2 on S298. We also
excluded Src being involved because inhibition of Src
activation by dasanitib had no inﬂuence on MEK activation
induced by overexpressing V1, V2, or GIT1. However,
overexpression of MAT2B variants and GIT1 activated Src,
the implication of which will require further study.
MAT2B and GIT1 overexpression not only enhanced
interaction between the Raf kinases and MEK1/2 but also
activated both Raf kinases in HepG2 cells and c-Raf in RKO
cells. Because RKO cells express a mutant B-Raf that is
constitutively active, overexpression of MAT2B or GIT1
had no effect on B-Raf activation but they still increased
MEK1/2 activity. This ﬁnding suggests that in RKO cells
the mechanism is independent of B-Raf activation.
Consistently, knockdown of c-Raf in RKO cells completely
blocked MEK1/2 activation by MAT2B and GIT1 over-
expression. In addition, knockdown of V1, V2, or GIT1
reduced c-Raf activation in both HepG2 and RKO cells.
B-Raf and c-Raf form homodimers and heterodimers,
with heterodimers exhibiting much higher kinase activity.5
Overexpression of MAT2B and GIT1 in both HepG2 and
RKO cells enhanced interaction between B-Raf and c-Raf.
Overexpressing V1, V2, or GIT1 also activated B-Raf,
c-Raf, and MEK1/2 and enhanced recruitment of B-Raf and
c-Raf to MEK1/2 in SW480 and Hep3B cells. Several
proteins have been reported to enhance B-Raf and c-Raf
dimerization, including Ras, 14-3-3, KSR1, and MLK3.5ajp.amjpathol.org - The American Journal of Pathology
Ras/Raf/MEK Activity RegulationThe in vitro assay using immobilized c-Raf revealed clearly
that the presence of the MAT2B-GIT1 complex facilitated
recruitment of B-Raf in the absence of any additional pro-
teins. This ﬁnding also suggests that MAT2B and GIT1 may
activate MEK in RKO cells via facilitating c-Raf/B-Raf
heterodimerization. MAT2B-GIT1 complex likely can also
stabilize c-Raf because the c-Raf protein but not mRNA
levels increased when they were overexpressed and
decreased when they were reduced. This can then further
contribute to activating Raf and downstream events.
Interestingly, although MAT2B and GIT1 interacted with
MEK1/2, c-Raf, and B-Raf in NCM460 cells, which are
normal human colonic epithelial cells, overexpressing V1,
V2, or GIT1 failed to enhance recruitment of c-Raf and
B-Raf to MEK1/2 or activate these kinases. The reasons for
the different response to V1, V2, and GIT1 overexpression
between malignant and nonmalignant cells are not clear.
One possibility is the lower expression level of GIT1 and
the dominant MAT2B variant V1 so that even when over-
expressed, the scaffold complex may not form efﬁciently to
affect recruitment of the Raf kinases or to activate them. In
addition, we and others have reported that NCM460 cells
respond differently to agents that induce apoptosis in colon
cancer cells, and others have also reported that NCM460
cells have different MAPK and c-Myc signaling responses
compared with colon cancer cells.22,23
Because MAT2B and GIT1 overexpression increased the
level of active Raf at Ras target sites (phosphorylation of
c-Raf on S338 and B-Raf on T598/S601) (Figure 3), the
next question was whether Ras was affected. Interestingly,
overexpression of MAT2B but not GIT1 increased Ras
protein levels in both HepG2 and RKO cells. This ﬁnding is
likely due to protein stabilization because mRNA levels
were unchanged. In terms of Ras protein regulation, it is
generally agreed that on activation by growth factors, such
as insulin-like growth factor 1, Ras translocates to the
plasma membrane and is farnesylated at the COOH termi-
nus, which is required for activation and membrane
anchorage.24 When Ras farnesylation is inhibited, Ras is
dislodged from the membrane and degraded.25 The insulin-
like growth factor 1 receptor stabilizes Ras by enhancing
farnesylation.24 More recently, H-Ras was found to be
polyubiquitylated and degraded via proteasome by Wnt/b-
catenin signaling.26 How MAT2B affects Ras protein sta-
bility will require further examination.
In vitro, MAT2B but not GIT1 can directly bind to
immobilized Ras, but in cells, overexpression of V1, V2, or
GIT1 can enhance recruitment of c-Raf and Ras to B-Raf.
This ﬁnding can be explained by the fact that overexpression
of GIT1 will also recruit more MAT2B to interact with Ras.
Overexpression of V1, V2, or GIT1 also activated Ras in
RKO cells that express wild-type Ras. Ras activity is regu-
lated by several mechanisms, including guanine nucleotide
exchange and lipid-based modiﬁcations, such as farnesyla-
tion, which are required for membrane translocation and
functionality.24 SOS is a well-known Ras activator thatThe American Journal of Pathology - ajp.amjpathol.orgtranslocates to the plasma membrane on growth factor acti-
vation, interacts with Ras, and facilitates Ras activation.27
However, we did not detect increased interaction between
Ras with SOS in cells overexpressing V1, V2, or GIT1 (data
not shown). Thus, the mechanism for MAT2B/GIT1 over-
expression to activate Ras is not due to their ability to help
Ras also recruit SOS. How MAT2B/GIT1 activates Ras will
be the subject of future investigation.
We previously found that increased V1 or V2 expression
in conjunction with GIT1 resulted in a much more aggressive
liver cancer phenotype as indicated by enhanced growth and
distant metastasis.4 We also found that these tumors exhibi-
ted increased MEK activity.4 Our current work conﬁrmed the
upstream signaling because increased V1, V2, and GIT1
expression in cell lines activated c-Raf and enhanced inter-
action of Ras with Raf kinases and recruitment of Raf kinases
to MEK in these tumors. Mutations in the Ras-Raf-MEK-
ERK signaling pathway are well known in many cancers,
and targeting this pathway has been the subject of intense
research.28 However, clinical success has been disap-
pointing,28 and paradoxical activation in Raf kinase can
occur with B-Rafespeciﬁc inhibitor (thought to be due to
enhanced heterodimerization of B-Raf and c-Raf).8 Our
ﬁnding that MAT2B and GIT1, which are overexpressed in
human liver and colon cancer,4 form a scaffold complex that
positively regulates Ras signaling at multiple steps suggests
that targeting this complex may be a novel and effective
approach in cancer therapy. Although multiple scaffold
proteins, such as KSR1/2, IQGAP1, MP1, and b-Arrestin1/2,
have been described to regulate Ras-Raf-MEK-ERK
signaling, to the best of our knowledge, none of them
interact with all the components of this signaling pathway.29
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